Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) announced on Thursday that it has entered into a global licence agreement with biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) for its PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody programme, including BAN1503 and BAN2803.
Under the terms of the agreement BioArctic will receive a USD100m upfront payment and up to USD1.25bn in milestone payments, as well as tiered royalties on global product sales.
Bristol Myers Squibb will be responsible for the development and commercialisation of the licensed products worldwide.
BioArctic's PyroGlu-Aβ antibody programme targets a specific, toxic form of amyloid-beta, a key protein implicated in Alzheimer's disease.
BAN2803 which utilises BioArctic's BrainTransporter technology to enhance drug delivery to the brain. This is the first license agreement for the BrainTransporter technology, opening up potential opportunities for future partnerships in various therapeutic areas.
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Eli Lilly and Co receives approval from FDA for Zepbound
YolTech Therapeutics updates data from Phase I/IIa clinical trial of YOLT-201
AstraZeneca's Tagrisso gains EU approval for advanced lung cancer treatment
Novo Nordisk's CagriSema shows superior weight loss in obesity trial
GSK's Jemperli-Zejula combination shows promise in ovarian cancer
Sapience Therapeutics' ST316 receives US FDA Orphan Drug Designation
Ionis Pharmaceuticals' TRYNGOLZA receives US FDA approval
BioArctic licenses PyroGlu-Aβ antibody programme to Bristol Myers Squibb
Thor Medical signs supply deal with AdvanCell
MOBILion Systems collaborates with Dr Oliver Schmitz to enhance metabolomics analysis
Abilita and Orion partner on antibody therapeutics for oncology and pain
Pharus Diagnostics unveils liquid biopsy test for early pancreatic cancer detection
Mendus reports positive topline data from ovarian cancer trial